DEC 23, 2018 11:22 PM PST

Type 2 Diabetes Drug May Treat Heart Failure Syndrome

WRITTEN BY: Nouran Amin

A drug used in the treatment of Type 2 Diabetes, by the name of Metformin, may soon be used to treat heart failure syndrome with preserved ejection fraction (HFpEF), a diagnosis that by year 2020 is predicted to affect 8% of people 65 or older. The study was carried out by the University of Arizona and shows that metformin was observed to relax a key protein present in the cardiac muscle known as titin—a protein that holds a significant role in allowing the heart to fill with blood prior to pumping it around the body.

Learn more about the anatomy of the human heart:

The condition of HFpEF involves the stiffness of the left ventricle which reduces the blood supply to the body despite proper contraction. HFpEF occurs in about half of all heart failure patients and is more common in women with risk factors including old age, hypertension, and obesity. As of now, no drugs are currently available for the treatment of HFpEF.

However, results of the study published in the Journal of General Physiology, concludes that metformin may soon be an effective therapeutic for HFpEF because it increases the left ventricular dilation and reduces the rate of heart failure in diabetic patients. The observations were seen in model mice with HFpEF-like symptoms that were given the drug. Metformin acts on titin to ultimately relax the left ventricle. Naturally, titin allows the cardiac muscle to recoil after stretching. Specifically, the drug adds phosphate groups on the titin causing it to become more complaint and allowing the heart muscle as whole to do the same.

Metformin is currently used for the management of Type 2 Diabetes. Now, research is suggesting it is a possible therapeutic for heart failure syndrome with preserved ejection fraction (HFpEF).

Credit: DiabetesSelfManagement.com

"We therefore conclude that metformin is a potential therapy for patients with HFpEF," says Henk L. Granzier at the Sarver Heart Center of the University of Arizona. "Because the drug is already approved and well tolerated in humans, using it to target titin stiffness presents a unique opportunity for immediate translation to the clinic."

Source: Journal of General Physiology, Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 05, 2018
Drug Discovery
NOV 05, 2018
Anti-Parasitic Drug Improves Long-term Clinical Outcomes in Chagas Disease
In a recent study published in PLOS Neglected Tropical Diseases, an anti-parasite drug by the name of ‘benznidazole’ may hold potential in impr...
NOV 10, 2018
Genetics & Genomics
NOV 10, 2018
Scientists Engineer a Better Way to Direct Evolution
Directed evolution is a Nobel-prize winning technique that has now been simplified and accelerated....
NOV 24, 2018
Drug Discovery
NOV 24, 2018
New Anti-Malarial Drug Target in Cancer
For decades, anti-malaria drugs--known as Chloroquines, have used to treat cancer. But the role in repurposing these drugs for slowing tumor growth have ne...
DEC 27, 2018
Cannabis Sciences
DEC 27, 2018
Parents Turning to Medical Marijuana to Treat Children's Autism
WHEC News in Rochester, New York, is reporting that more adults are turning to medical marijuana to treat their child's autism. The parents claim that...
JAN 03, 2019
Health & Medicine
JAN 03, 2019
Antibiotic Resistance - A Global Health Threat
Antibiotics play a critical role in fighting off bacterial infections. Since the discovery of the first antibiotic, Penicillin, antibiotic treatment became an effective and safe tool which is...
JAN 20, 2019
Drug Discovery
JAN 20, 2019
Multiple sclerosis treatments hold long-term benefits
An international study, led by the Clinical Outcomes Research unit (CORe) at Royal Melbourne Hospital and University of Melbourne, concludes the importance...
Loading Comments...